Look at it this way. Institutional investors will not invest in Poet as it stands right now. Only when a big customer, large NRE and/or a recurring Poet-specific revenue stream is announced, with matching Poet-specific (not DL) products in the market would this company be palatable to such investors.

The SP will be more than double the current price when any of the above come into play. Having said that, I don't think a financing is in the cards. The MD&A specifically stated that Poet has sufficient funds for beyond August, 2017.

There's lots of companies that have gained analyst coverage without doing a financing. Right now it's all about execution and the numbers that will follow from it.